18-Fluorodeoxyglucose positron emission tomography/computed tomography in the management of aggressive non-Hodgkin's B-cell lymphoma
| Data(s) |
13/07/2016
13/07/2016
2012
26/09/2012
|
|---|---|
| Resumo |
18-Fluorodeoxyglucose (FDG-PET/CT) is an established imaging modality that has been proven to be of benefit in the management of aggressive B-cell non-Hodgkin's lymphoma, such as diffuse large B-cell lymphoma and advanced stage follicular lymphoma. The combination of anatomic and functional imaging afforded by FDG-PET/CT has led to superior sensitivity and specificity in the primary staging, restaging, and assessment of response to treatment of hematological malignancies when compared to FDG-PET and CT alone. The use of FDG-PET/CT for post treatment surveillance imaging remains controversial, and further study is needed to ascertain whether this modality is cost effective and appropriate for use in this setting. |
| Formato |
application/pdf |
| Identificador |
Shelly, M. J., McDermott S., O'Connor O. J. and Blake M. A. (2012) '18-Fluorodeoxyglucose positron emission tomography/computed tomography in the management of aggressive non-Hodgkin's B-cell lymphoma', ISRN Hematology, 456706. http://dx.doi.org/10.5402/2012/456706 456706 (1) 456706 (9) 2090-441X 2090-4428 http://hdl.handle.net/10468/2869 10.5402/2012/456706 IRSN Hematology 456706 |
| Idioma(s) |
en |
| Publicador |
Hindawi Publishing Corporation |
| Direitos |
© 2012 M. J. Shelly et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. https://creativecommons.org/licenses/by/3.0/ |
| Palavras-Chave | #Lymphoma #FDG-PET/CT #Fluorodeoxyglucose #Non-Hodgkin's lymphoma |
| Tipo |
Article (non peer-reviewed) |
